Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Study acronym: COMET-HF
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 208 to 209
  2. Primary endpoints: details revised at 1 of 1 entry Show 4 more changesShow less
    • Trial sites expanded: 205 → 208 locations
    • Eligibility criteria expanded, about 29 words
    • Secondary endpoints: details revised at 2 of 7 entries
    • Publications: details revised at 1 of 1 entry
  3. Trial sites expanded: 201 → 205 locationsv25
  4. Study sites: 199 to 201v24
  5. Trial sites expanded: 196 → 199 locationsv23
  6. Trial sites expanded: 191 → 196 locationsv22
  7. Trial sites expanded: 188 → 191 locationsv21
  8. Study sites: 187 to 188v20
  9. Study sites: 185 to 187v19
  10. Study sites: 183 to 185v18
  11. Study sites: 181 to 183
    • Eligibility criteria expanded, about 136 words
    v17
  12. Study sites: 177 to 181v16
  13. Study sites: 171 to 177v15
  14. Study sites: 169 to 171v14
  15. Study sites: 84 to 169v13
  16. Study sites: 77 to 84v12
  17. Study sites: 72 to 77v11
  18. Study sites: 63 to 72v10
  19. Study sites: 50 to 63v9
  20. Study sites: 33 to 50v8
  21. Study sites: 18 to 33v7
  22. Study sites: 13 to 18v6
  23. Study sites: 9 to 13v5
  24. Study sites: 7 to 9v4
  25. Study sites: 5 to 7v3
  26. Study sites: 1 to 5v2 Show 4 more changesShow less
    • Start date changed from estimate of Dec 2024 to Dec 19, 2024
    • Eligibility criteria shortened, about 21 words
    • Secondary endpoints revised (7)
    • Study description expanded, about 15 words
  27. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Cytokinetics
8 trials monitored
See 2 trials at risk
Heart Disease
8,814 trials monitored
See 428 trials at risk
Heart Failure
2,000 trials monitored
See 115 trials at risk
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
Trial Details
NCT Number NCT06736574
Lead Sponsor Cytokinetics
Conditions
(from sponsor)		 Heart Failure, Heart Failure With Reduced Ejection Fraction
Related terms Heart Failure
Enrollment 1,800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov